Tyler Sandahl, PharmD

Experts weigh meaningful innovation in frontline myeloma therapy against incremental gains, spotlighting patient out-of-pocket costs, financial counseling, and payer-driven formulary decisions.

Experts discuss how MRD testing in myeloma increasingly guides frontline care, yet unanswered questions still limit using MRD as the sole benchmark.

BCMA ADC belantamab added to DRd shows striking MRD negativity in early myeloma trials, but eye toxicity and access shape frontline use.

Cepheus data shows durable 6‑year control with DVRd, prompting new counseling and tailored dosing for frail, transplant‑ineligible myeloma patients.

Experts debate quadruplet myeloma therapy, MRD-guided de-escalation, and risk-adapted intensification—plus how payers may respond.

Experts weigh quadruplet vs triplet myeloma therapy, tailoring to frailty and clots, and push early CAR-T/BCMA options for high-risk patients.

The panelists examined the significant progress made in frontline multiple myeloma treatment while emphasizing that true satisfaction will only come when more patients achieve a durable cure and can transition off maintenance therapy entirely, identifying MRD-guided treatment discontinuation as one of the most promising pathways toward that goal.

Experts unpack new myeloma regimens—quadruplet induction, dual maintenance, earlier smoldering therapy—plus real-world access and cost hurdles.